FUJI PHARMA CO., LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,529 JPY | +0.72% |
|
-4.56% | -12.08% |
| 2023 | Mithra Pharmaceuticals' License Partner Files for Estelle's Marketing Approval in Japan; Shares Jump | MT |
| 2023 | Alvotech Partner Secures Marketing Approval for Stelara Biosimilar AVT04 in Japan | MT |
Business Summary
Number of employees: 1,621
Sales per Business
| JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Product - Hormones
39.3
%
| 12,073 | 34.1 % | 16,047 | 39.3 % | +32.92% |
Product - Others
24.1
%
| 9,032 | 25.5 % | 9,846 | 24.1 % | +9.01% |
Product - Diagnostic Agent
18.8
%
| 7,447 | 21.0 % | 7,672 | 18.8 % | +3.02% |
Product - Metabolic Drugs
5.0
%
| 1,486 | 4.2 % | 2,056 | 5.0 % | +38.36% |
Merchandise - Others
3.4
%
| 930 | 2.6 % | 1,409 | 3.4 % | +51.51% |
Product - Tissue Cell Function Drug
2.5
%
| 948 | 2.7 % | 1,010 | 2.5 % | +6.54% |
Merchandise - Hormones
2.3
%
| 1,227 | 3.5 % | 925 | 2.3 % | -24.61% |
Product - Nervous System and Sensory Organ Agents
1.8
%
| 924 | 2.6 % | 749 | 1.8 % | -18.94% |
Product - Antibiotics and Chemotherapeutic Agents
1.5
%
| 651 | 1.8 % | 630 | 1.5 % | -3.23% |
Product - Cardiovascular Drugs
1.0
%
| 553 | 1.6 % | 409 | 1.0 % | -26.04% |
Merchandise - In-vitro Diagnostics Drugs
0.3
%
| 149 | 0.4 % | 130 | 0.3 % | -12.75% |
Sales per region
| JPY in Million | 2022 | Weight | 2023 | Weight | Delta |
|---|---|---|---|---|---|
Japan
100.0
%
| 35,426 | 100.0 % | 40,889 | 100.0 % | +15.42% |
Managers
| Managers | Title | Age | Since |
|---|---|---|---|
Takayuki Iwai
PSD | President | 60 | 30/11/06 |
Hirofumi Imai
CHM | Chairman | 60 | 31/03/87 |
Hiroshi Uji
ADM | Chief Administrative Officer | - | - |
Toyoyuki Kamide
BRD | Director/Board Member | 59 | 31/03/00 |
Takanori Matsuo
SAM | Sales & Marketing | - | - |
Shuhei Morita
PRN | Corporate Officer/Principal | - | - |
Seiichi Inoue
AUD | Comptroller/Controller/Auditor | 65 | 31/03/14 |
| Corporate Officer/Principal | 53 | 31/03/94 |
Members of the board
| Members of the board | Title | Age | Since |
|---|---|---|---|
Keiji Hirai
BRD | Director/Board Member | 74 | 30/11/16 |
| Director/Board Member | 71 | 30/11/17 | |
Hirofumi Imai
CHM | Chairman | 60 | 31/03/87 |
Toyoyuki Kamide
BRD | Director/Board Member | 59 | 31/03/00 |
Tadahiro Kozawa
BRD | Director/Board Member | 74 | 01/10/93 |
| Corporate Officer/Principal | 53 | 31/03/94 | |
Seiichi Inoue
AUD | Comptroller/Controller/Auditor | 65 | 31/03/14 |
Takayuki Iwai
PSD | President | 60 | 30/11/06 |
Yukiko Araki
BRD | Director/Board Member | 63 | 30/11/20 |
Keiko Kiyama
BRD | Director/Board Member | 64 | 30/11/20 |
Share class
| Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
|---|---|---|---|---|---|
| Stock A | 0 | 24,753,800 | 12,606,585 ( 50.93 %) | 441,500 ( 1.784 %) | 50.93 % |
Holdings
| Name | Equities | % | Valuation |
|---|---|---|---|
ALVOTECH 1.68% | 4,475,691 | 1.68% | 61,093,182 $ |
| 4,913,220 | 1.85% | 48,736,882 $ | |
FUJI PHARMA CO., LTD. 1.75% | 433,400 | 1.75% | 4,379,030 $ |
Company contact information
Fuji Pharma Co., Ltd.
Seito Kaikan, 6/F 5-7 Sanban-cho
102-0075, Tokyo
+81 3 3556 3344
http://www.fujipharma.jp
Sector
Sales per Business
Sales per region
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1,518
JPY
Average target price
2,090
JPY
Spread / Average Target
+37.68%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -12.08% | 236M | |
| +31.51% | 588B | |
| -3.42% | 364B | |
| +18.02% | 326B | |
| +4.27% | 285B | |
| +15.25% | 239B | |
| +10.13% | 210B | |
| -7.16% | 200B | |
| +8.12% | 167B | |
| -1.42% | 161B |
- Stock Market
- Equities
- 4554 Stock
- Company Fuji Pharma Co., Ltd.
